Evidence map›Paper›PMID 39791582›Full record

Observational studyInvestigative and clinical urology2025

Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek

Jee Soo Park, Won Sik Jang, Jongchan Kim, Moon-Hwa Park, Won Sik Ham

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Investigative and clinical urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Jee Soo ParkDepartment of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.ORCID 0000-0001-9976-6599
Won Sik JangDepartment of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.ORCID 0000-0002-9082-0381
Jongchan KimDepartment of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.ORCID 0000-0002-0022-6689
Moon-Hwa ParkHanmi Pharmaceutical Co., Ltd., Seoul, Korea.ORCID 0009-0006-5281-7348
Won Sik HamDepartment of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. uroham@yuhs.ac.ORCID 0000-0003-2246-8838

Funding

Hanmi Pharmaceutical Co., LtdNRF 2019R1A2C1002863NRF 2022R1A2C2003831
6 · The paper itself

Abstract

purposeMirabegron, the first-in-class beta-3 agonist, is the mainstay medication for overactive bladder (OAB). The aim of this study was to investigate the efficacy and safety of generic drugs of mirabegron (Mirabek MATERIALS AND

methodsAdult patients with OAB prescribed Mirabek

resultsAmong 1,714 patients, Mirabek

conclusionsThis study demonstrated that Mirabek

Indexed as

AcetanilidesThiazolesUrinary Bladder, OveractiveAdrenergic beta-3 Receptor AgonistsAdultAgedDrugs, GenericFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeUrological AgentsAcetanilidesAdrenergic beta-3 Receptor AgonistsDrugs, GenericmirabegronThiazolesUrological AgentsAdrenergic beta-3 receptor agonistsMirabegronUrinary bladder, overactive

Identifiers

PMID39791582
PMCPMC11729222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.